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Many drug interactions are discovered serendipitously. However, 
it is possible to predict the potential for an interaction between two 
drugs based on the physical, chemical, pharmacokinetic, and pharmaco-
logic properties of those drugs. The effect of such an interaction on 
the patient is dependent on many factors, including the nature and 
magnitude of the interaction, and is therefore difficult to predict. A 
potential interaction would best be studied in a controlled experimental 
setting to limit the interference of variables and to protect the 
subjects. 
A potential interaction may exist between rifampin and theophyl-
line. Rifampin has been shown to induce microsomal enzymes and to 
1 2 
alter the clearance of many drugs. * Theophylline is metabolized by 
microsomal enzymes and has demonstrated an increase in clearance 
3 4 
following conditions that increase microsomal activity. * To date, 
the interaction between these two drugs in humans has not been 
described, but a recent study demonstrated no interaction between these 
5 
two drugs in rabbits. However, since the effect of rifampin on drug 
6—9 
clearance has shown interspecies variation, an interaction between 
rifampin and theophylline may exist in humans. 
Rifampin Interactions 
Rifampin increases the clearance rate, decreases the half-life, 
and decreases the steady-state serum concentrations of several, but not 
all, hepatically 'metabolized drugs.1,2,10"40 Rifampin has been shown 
to affect these pharmacokinetic parameters of antipyrine,chlor-
17 18 19 20 21 propamide, clofibrate, dapsone, diazepam, • digitoxin, digox-
^ 22,23 , 24,25 . . t ,, 26-28 . . , . in, estrogens, glucocorticosteroids, hexobarbi-
16 29 30 31 32 tal, ' * mexiletine, progestogens (norethindrone ), quini-
13 22 33 15 12 34> dine, ' ' rifampin itself, thyroxine, tolbutamide, vitamin D 
1 <4 32-37 (25-hydroxycholecalciferol )» and warfarin. . Several of these 
interactions have resulted in potentially dangerous situations, such as 
pregnancy or breakthrough bleeding in patients on oral contraceptives 
and decreased response to glucocorticosteroids in patients with nephro-
27 28 tic syndrome or Addison's disease. Alternatively, the administra-
38 
tion of rifampin had no effect on the clearance of clonidine and 
39 40 
isoniazid, 5 which are both metabolized in the liver. 
The interactions that occur with rifampin are thought to be the 
result of increased hepatic metabolism of the affected drug secondary 
1 2 
to microsomal induction by rifampin. ' Rifampin has caused prolifer-
ation of smooth endoplasmic reticulum, which is associated with an 
increase in microsomal enzymes, in both human and guinea-pig hepato-
41 
cytes. Changes in drug clearance occur 6 to 14 days following the 
initiation of rifampin administration11' ^ and return to 
pretreatment values 14 to 16 days following the discontinuation of 
rifampin.10'16 
Although this time course and changes in hepatocyte morphology are 
consistent with the effect of rifampin on microsomal enzymes, other 
mechanisms of increased clearance of drugs by rifampin are possible and 
include: increased liver blood flow, increased hepatocyte uptake or 
biliary secretion of the drug, or decreased protein binding of the 
affected drug. However, rifampin administration did not change the 
16 
clearance of indocyanine green, an agent used to assess liver blood 
flow. Also, rifampin has been postulated to decrease the hepatocyte 
43 
uptake or the biliary secretion of bromsulphalein and bilirubin, and 
44 
has increased sex hormone binding capacity and the protein binding of 
29 30 
oxprenolol and propranolol. ' Since these studies on other poten-
tial mechanisms of rifampin's effect on drugs provide results which 
would cause either no change or a decrease in the clearance rate of the 
affected drugs, the induction of microsomal enzyme activity is the most 
probable reason for rifampin's ability to increase the clearance of 
certain drugs. 
Theophylline Interactions 
Theophylline clearance has been decreased by many conditions or 
3 45 drugs. These include allopurinol (600 mg per day but not 300 mg per 
day^'^), dmetidine^®,':^ (not in older patients"^) , erythromycin,"**" 
55 55 56 metoprolol (in smokers only ), propranolol, troleandomycin, 
57 58 59 60—63 obesity, ' high-carbohydrate diet, influenza vaccine (not in 
6A 65 66 57 67 all studies ), viral illness, ' congestive heart failure, ' 
68 69 cirrhosis, and severe pulmonary obstruction. These interactions 
have resulted in theophylline toxicity in some cases, 
3 
Increases in theophylline clearance have also been noted. 
Conditions or drugs that have increased theophylline clearance include: 
70 71 72 isoproterenol, phenobarbital (but not in all studies ) , pheny-
73 74 7577 76 toin, ' smoking of tobacco ~ or marijuana, ingestion of charcoal-
broiled beef,78 a high-protein diet,59 and a high-protein lov-carbohy-
79 
drate diet. Decreased therapeutic benefit from theophylline, second-
ary to increased clearance of theophylline, has been noted in some 
reports. 
Theophylline is extensively metabolized, and only 7 to 13% of the 
4 
drug is excreted unchanged in the urine. The metabolism of theophyl-
line, shown in Figure 1, involves mixed-function oxidation (Cytochrome 
F^q), oxidation (xanthine oxidase and Cytochrome P^g), and demethy-
4 
lation. Many of the interactions which have resulted in decreased or 
increased clearance of theophylline are thought to involve changes in 
3 
the liver metabolism of theophylline. However, these alterations in 
theophylline clearance are not always consistent, as demonstrated in 
reports of both changes and lack of changes in theophylline clearance 50 7L 72 following cimetidine and phenobarbital ' administration. 
Rationale 
Although rifampin and theophylline have been used clinically for 
many years, there are no reports on the interaction between them in 
.humans. These medications may be used concurrently in a patient. If 
rifampin administration increases the clearance of theophylline, 
patients could experience an exacerbation of their lung disease when 
rifampin therapy is added to a stable regimen of theophylline. The 
prior knowledge of the existence of such an interaction would alert 
clinicians to closely monitor the patients at risk. Therefore, the 
following study was conducted to determine the effect of rifampin on 
theophylline pharmacokinetics. 
MATERIALS AM) METHODS 
The protocol and the informed consent form for this study were 
approved by the Institutional Review Board (Review Committee for 
Research with Human Subjects) at the University of Utah Medical Center. 
The project was partially funded and supported by the Clinical Research 
Center at the Medical Center. 
Subjects 
The inclusion and exclusion criteria explained below were used to 
select ten nonsmoking healthy male volunteers between 18 and 45 years 
of age who were willing and able to give informed written consent and 
participate In this study. Potential subjects were excluded for the 
presence or history of any serious chronic illness, or if their total 
body weight was greater than 20% over their ideal body weight (see 
Appendix 1 for the ideal weight determination formula). Additionally, 
subjects were excluded if they showed any abnormality of the following 
laboratory tests; total or direct bilirubin, serum creatinine, blood 
urea nitrogen, serum albumin, or total serum protein. Other 
laboratory-test exclusions included: any other liver function test 
result greater than 130% of the upper limit of normal for that test; 
any complete blood count value (red blood cell count, hematocrit, 
hemoglobin, white blood cell count, platelet count) less than 90% of 
the lower limit of normal for that test; or hematuria or proteinuria 
greater than 1+ on spot urinalysis. 
Screening 
Volunteers were recruited and screened for eligibility. This 
screening included a physical examination, measurement of weight, 
estimation of height, medical and medication history, urinalysis, 
complete blood count, and blood chemistry analysis. Blood chemistry 
analysis included the measurement of sodium, chloride, potassium, 
carbon dioxide, creatinine, urea nitrogen, glucose, alanine aminotrans-
ferase, aspartate aminotransferase, lactic dehydrogenase, alkaline 
phosphatase, total and direct bilirubin, albumin, total protein and 
cholesterol. Laboratory tests were repeated at the end of the study. 
Eligible subjects were asked to read and sign an informed consent form, 
and were evaluated for their willingness and ability to participate in 
this study. Appendix 2 contains a copy of the informed consent form 
and the form used to collect the screening visit data. 
Aminophylline Administration 
Aminophylline, the ethylenediamine salt of theophylline containing 
85% theophylline, was administered twice: one to seven days before 
rifampin was started, and again on the final day of rifampin administra-
tion. The dose of aminophylline ranged from 5,9 to 6.8 mg/kg for each 
administration (or 5.1 to 5.8 mg/kg of theophylline). One subject 
received 6.7 to 6.8 mg/kg of aminophylline and the other nine subjects 
received 5.9 to 6.2 mg/kg of aminophylline. The aminophylline (25 tug/ml 
from Aminophylline Injection, U.S.P.; LyphoMed Inc.; Melrose Park, IL) 
was diluted with 5% dextrose in water to a total volume of 38 milli-
liters. Harvard Mini-Infuser 200 ® pumps (BARD, Inc.; North Reading, 
MA) were used to administer the aminophylline over 20 minutes through a 
cannula which was inserted into an antecubital vein. 
The subjects were admitted to the Clinical Research Center before 
the start of the infusion,, and were monitored closely during the 
aminophylline administration. Open-ended questions were used to 
Identify any adverse effects. Blood pressure and heart rate were 
measured before, during and after the aminophylline infusion. Subjects 
were also weighed each day of aminophylline administration. Appendix 2 
contains a copy of the form used to collect these data and sampling 
times, 
Rifampin Administration 
Subjects were instructed to take 600 mg of rifampin each morning 
for two weeks, starting one to seven days following the first aminophyl-
line infusion and ending the morning of the second aminophylline 
infusion. Each subject received 28 capsules of rifampin (300 mg per 
capsule; Rimactane® ; Clba Pharmaceutical Co.; Summit, NJ) with instruc-
tions to take two capsules in one dose each morning. One subject, who 
experienced adverse reactions which were possibly secondary to rifam-
pin, was instructed to take 300 mg. of rifampin twice daily. Subjects 
were contacted every one to four days to assess adverse effects and 
compliance, and were also asked to keep a record of compliance and 
adverse effects on a form supplied (see Appendix 2 for a copy of this 
form). Compliance was also assessed through capsule counts at the 
completion of rifampin administration. 
Medication and Diet Restrictions 
To decrease the potential for interference of certain variables, 
subjects were asked to limit their use of medications or certain diet 
items. Subjects were asked to decrease their caffeine intake for two 
days prior to and one day following aminophylline administration. 
Subjects were also asked to refrain from taking any other medications 
during the study, and to limit their intake of alcoholic beverages 
during rifampin administration. 
Serum Sample Collection 
Blood samples were obtained through a cannula or by way of veni-
puncture in the arm opposite that into which the aminophylline was 
infused. The cannula, which was kept patent by the instillation of one 
to two milliliters of heparin (100 units/ml), was used to obtain the 
first nine or ten samples for each aminophylline infusion. 
Blood was collected in 5 milliliter samples at the following times 
relative to the start of the aminophylline infusion; zero, 10, 20, 30, 
and 40 minutes; 1, 2, 4, 8, 12, and 24 hours. The blood was allowed to 
clot at room temperature for at least two hours and then centrifuged at 
2500 rpm for 15 minutes. The serum was then collected from each 
specimen and stored frozen (-20 degrees centigrade) in individual 
containers for 4 to 56 days before analysis. 
Theophylline Analysis 
The serum samples were analyzed for theophylline concentration by 
® 
the fluorescence polarization immunoassay technique (TDx , Abbott 
Laboratories; North Chicago, IL). This immunoassay is routinely used 
to analyze theophylline concentrations at University Hospital. All 
samples were analyzed only once on the same day in the Clinical Toxicol-
ogy Laboratory. The manufacturer reported linear results from 0.3 to 
40 meg/ml with this assay, and the Clinical Toxicology Laboratory 
reported a lower limit of detection of 0.5 mcg/ml. Quality control 
data provided by this laboratory demonstrated run-to-run coefficients 
of variation of 0.8, 2.2 and 6.6% at mean theophylline concentrations 
of 18.6, 11.7, and 4.8 mcg/ml respectively. Quality control data 
provided by the manufacturer demonstrated run-to-run coefficients of 
variation of 1.5, 2.3, and 3.1% at mean theophylline concentrations of 
26.4, 12.3, and 7.2 meg/ml respectively. The Clinical Toxicology 
Laboratory also demonstrated a within run coefficient of variation of 
5.4% at a mean theophylline concentration of 2.4 mcg/ml. 
Pharmacokinetic Description and Calculation 
For each aminophylline administration, pharmacokinetic calculations 
were performed using all theophylline concentrations. Appendix 1 
contains the equations used in these calculations. 
Graphs were prepared for each patient and for the group as a whole 
using the semi-logarithmic plot of theophylline concentration versus 
time data. The two group graphs contained average theophylline concen-
tration values for each scheduled time. One of these graphs contained 
data from all ten subjects, while the other contained data from only 
eight subjects (Subjects #2 and #5 were excluded) . For these group 
graphs, theophylline concentrations in the terminal phase of elimination 
which were obtained at times distant from the scheduled times .were 
corrected to the scheduled times using the terminal elimination rate 
constant calculated for that infusion. 
The area under the serum theophylline concentration versus time 
curve was calculated using the trapezoidal method. This method includ-
ed linear trapezoidal analysis up to the peak concentration followed by 
the logarithmic trapezoidal analysis to the last measureable concentra-
tion. Linear extrapolation to infinity was then used to determine the 
area beyond the final point, and the percent extrapolated was calculat-
ed. The total area was the sum of the results of these three analyses. 
Iff 
The clearance .rate was calculated using the area under the curve 
value, the dose of theophylline (from aminophylline) administered, and 
the weight of the subject on the day of that infusion. 
The terminal elimination rate constant (Beta) and half-life were 
determined through the graphic and mathmatical evaluation of data. The 
semi-logarithmic plot of serum theophylline concentration versus time 
data was used to visually determine the terminal portion of the plot 
that approximated a straight line. Least squares analysis was used to 
determine the slope of this line, which corresponded to the negative 
value of Beta. The terminal elimination half-life was then calculated 
using the elimination rate constant. Correlation coefficient, coeffi-
cient of determination, and the t-test statistic were calculated for 
each line. 
The apparent volume of distribution of the terminal phase was 
calculated from the intercept of the terminal elimination line (deter-
mined in the calculation of the terminal elimination rate constant), 
the dose of theophylline (from aminophylline) administered, and the 
weight of the subject on the day of that infusion. 
Statistical Analysis 
Due to the variability of theophylline pharmacokinetics in the 
subjects and to the small number of subjects studied (ten), a nonpara-
metric test was felt to be the most appropriate to analyze these data. 
The nonparametric test used was the Wilcoxon matched-pair eigned-rank 
two-tailed test. Statistical significance was defined as an alpha 
level of 5% or less. 
RESULTS 
" Population 
The ten male subjects who participated in this study were all 
nonsmoking healthy Caucasians. The mean age was 30 years with a range 
of 23 to 42 years. The mean weight was 80 kilograms, and ranged from 
69 to 89 kilograms. 
Theophylline Concentration versus Time Plots 
Semi-logarithmic plots of serum theophylline concentration versus 
time data appear in Figures 2 through 13. Figures 2 through 11 present 
the data for each subject. The mean and standard deviation of the 
theophylline concentrations at each sampling time for all ten subjects 
and eight subjects appear in Figures 12 and 13 respectively. Figure 13 
does not contain the data from subjects #2 and #5. Subject #2 received 
a higher dose of theophylline than all other subjects. Subject #5 
demonstrated an unexplained increase in theophylline concentration 
following the end of the aminophylline infusion. In all of these 
graphs, the descending slope of the data collected after rifampin 
administration is steeper than that of the data collected before 
rifampin was given. 
Area Under the Concentration Versus Time Curve 
The area under the curve data presented in Table 1 are the results 
of the analysis by the method combining linear trapezoidal, logarithmic 
trapezoidal, and extrapolation to infinity analyses. Area under the 
curve values before rifampin had a mean (± standard deviation [SD]) of 
104 (±29) mg-hours/liter (range 75 to 170), and following rifampin all 
subjects demonstrated a decrease in these values to mean (±SD) of 
76 (±19) mg-hours/liter (range 54 to 105). Statistical significance 
between these values was demonstrated by the Wilcoxon matched-pair 
signed-rank two-tailed test (p < 0.02). 
Clearance Rate 
Clearance rates are presented in Table 2, and all subjects demon-
strated an increase in theophylline clearance following rifampin 
administration. Before rifampin, the mean (±SD) theophylline clearance 
rate was 0.88 (+0.21) ml/min/kg (range 0.56 to 1.22), and after rifampin 
the mean clearance (+SB) increased to 1.21 (±0.29) ml/min/kg (range 
0.92 to 1.54). These changes also demonstrated statistical 
significance (p < 0.02). 
Terminal Elimination Rate Constant (Beta) and Half-life 
As shown in Tables 3 and 4, all patients demonstrated an increase 
in the terminal elimination rate constant (Beta) and a decrease in the 
terminal half-life of theophylline following as compared to before 
rifampin administration. Beta increased from a mean (+SD) of 0.104 
(± 0.023) hours"1 (range 0.068 to 0.144) before rifampin to a mean 
(+SD) of 0.149 (+0.029) hours-1 (range 0.117 to 0.203) after rifampin. 
The half-life decreased from a mean (±SD) of 7.0 (±1.7) hours (range 
4.8 to 10.2) before rifampin to a mean (±SD) of 4.8 (±0.9) hours (range 
3.4 to 5.9) after rifampin administration. The statistical analysis of 
these parameters yielded statistical significance (p < 0.02). 
Apparent Volume of Distribution of the Terminal Phase 
The data for the apparent volume of distribution of the terminal 
phase, 'presented in Table 5, show inconsistent changes among subjects 
after rifampin administration. The mean (+SD) apparent volume of 
distribution of theophylline was 0.51 (±0.05) liters/kg before and 0.50 
(±0.05) liters/kg after rifampin administration. However, this volume 
of distribution decreased in six subjects (mean percentage change of 
-91 and range of -4 to -19%) and increased in four subjects (mean per-
centage change of 9% and range of 2 to 19%) after rifampin. Statistical 
analysis of these data did not demonstrate statistical significance 
(p >0.27). 
Lines Defining the Terminal of Elimination 
The lines which were used to determine the terminal elimination 
rate constant, half-life and apparent volume of distribution were 
subjected to linear regression analysis; Every line demonstrated 
correlation coefficients less than -0.988, and only one line had a 
value greater (less negative) than -0.990. Coefficients of determina-
tion were greater than 0,977 for all lines and greater than 0.990 in 
all but two lines. A t-test revealed p < 0.001 for all lines. 
Adverse Effects 
All subjects experienced at least one adverse effect from the 
medications during the study, but no subject was withdrawn from the 
study. Mild to moderate gastrointestinal discomfort was noted with 
both drugs. Aminophylline caused nervousness, slight tremor, and 
lightheadedness in most subjects. Rifampin was thought to cause 
headache in at least one subject. Rifampin discolored the urine of all 
subjects, feces in most subjects, and tears in one subject. One 
subject demonstrated a slight increase in blood urea nitrogen and 
another subject demonstrated a slight elevation in aspartate aminotrans-
ferase and proteinuria at the end of the study. All adverse effects 
and laboratory abnormalities resolved soon after the end of the study. 
Compliance 
Through capsule counts, diary entries, and oral communication; all 
subjects were determined to have complied by taking the rifampin every 
day of the prescribed 14 days. Also, all subjects denied caffeine 
intake for 18 hours before and 24 hours following the infusion of 
aminophylline. 
DISCUSSION 
Certain pharmacokinetic parameters of theophylline were changed by 
two weeks of rifampin administration in the healthy nonsmoking male 
subjects involved in this study. Rifampin decreased the area under the 
serum theophylline concentration versus time curve and the terminal 
half-life, and increased the clearance rate and Beta (the terminal 
elimination rate constant) of theophylline in all ten subjects. These 
results were statistically significant (p < 0.02). The terminal phase 
volume of distribution of theophylline was not consistently altered by 
rifampin. 
5 
. In contrast to the results of this study, Self, et al reported a 
lack of statistically significant change in theophylline pharmacokine-
tics following rifampin administration in rabbits. Interspecies 
variation has been demonstrated in the ability of rifampin to increase 
6-9 
the clearance of certain drugs, but rabbits and human beings have 
not been directly compared. Additionally, Self's study population of 
three rabbits may not have been large enough to detect a statistical 
difference. 
The control pharmacokinetic parameters of theophylline, those 
calculated before rifampin administration, from this study were 
compared to values reported elsewhere in similar populations. Other 
studies have reported mean clearance rates ranging from 0.75 to 1.25 
compared to the mean clearance rate in this study 
of 0,88 ml/min/kg. Mean terminal elimination half-lives vary from 5.2 
to 8.5 hours in other reports,^5»46»52 54 c o m pare(j t 0 ^g m e a n half-
life of 7.0 hours in this study. Values of the terminal phase volume of 
52-54 
distribution range from 0.41 to 0.69 liters/kg in other studies, 
compared to ~ the range of 0.44 to 0.57 liters/kg in this study. 
Although statistical analysis was not used in these comparisons, the 
pharmacokinetic parameters of theophylline before rifampin administra-
tion in this study are within the range of values reported in other 
studies. 
Analysis of the results utilizing the relationships between these 
pharmacokinetic parameters will help to determine the pharmacokinetic 
nature of this interaction. The area under the serum concentration 
versus time curve is proportional to the dose administered and inverse-
ly proportional to the clearance rate. The dose of theophylline (from 
aminophylline) varied only slightly (less than 3.5%) before and after 
rifampin administration, so the decrease in the area under the curve 
(mean of 27%, range 10 to 41%) is mostly a result of the increase in 
clearance. Clearance is defined as the product of the elimination rate 
constant and the volume of distribution. The terminal elimination rate 
constant (Beta) increased in every subject (mean of 44%, range 36 to 
72%) but the volume of distribution changed inconsistently (mean of 
-1%, range -19 to +19%). Therefore, the increase in clearance (mean of 
40%, range 12 to 65%) is probably a result of the increase in the 
elimination rate when evaluating the group as a whole. As a result, 
the pharmacokinetic mechanism of this interaction was most likely the 
ability of rifampin to increase the terminal elimination rate constant 
of theophylline, but other mechanisms are possible. 
The properties of each drug also provide insight into the potential 
mechanism of this interaction. Rifampin has been noted to induce 
microsomal enzyme activity in the liver, and to increase the hepatic 
1 2 
metabolism of many drugs. ' * Theophylline is metabolized, in part, by 
microsomal enzymes and is affected pharmacokinetically by drugs that 
3 4 
induce or inhibit those enzymes, ' Since only 7 to 13% of theophyl-
line is excreted unchanged in the urine, clearance of this drug is 
highly susceptible to changes in its metabolism. Although this study 
did not evaluate the induction of hepatic microsomal enzymes, the 
increase in the terminal elimination rate constant of theophylline 
caused by rifampin administration is most likely the result of the 
induction of the activity or number of those enzymes by rifampin. 
The clinical relevance of these results can only be speculated 
upon. The mean decrease of 27% in the theophylline area under the 
curve that followed rifampin administration could theoretically result 
in a 27% decrease in steady-state theophylline concentrations. Since 
the therapeutic effect of theophylline is considered to be concentra-
tion dependent, a decrease in theophylline concentration of this 
magnitude may result in a decrease in the therapeutic effect of that 
drug. Also, an increase in theophylline concentration is possible when 
rifampin is discontinued in a patient who was stabilized on both drugs. 
This increase in theophylline concentration could lead to toxicity. 
Clinical and experimental differences need to be evaluated before 
one can extrapolate the results of this study to all patients. For 
example, older patients may not demonstrate the same changes as younger 
subjects in theophylline clearance and elimination rates induced or 
inhibited by certain drugs. Cimetidlne has decreased theophylline 
48 49 
clearance in many subjects, but not in subjects 61 to 73 years of 
50 
age. Subjects in the current study were 23 to 42 years old. Also, 
these subjects were healthy, nonobese, nonsmoking males who abstained 
from caffeine before, during and after aminophylline administration. 
However, the patients who may receive these medications concurrently 
could potentially be ill (lung or heart disease), obese, smokers, 
and/or coffee drinkers. Each of these factors affect the pharmacokin-
etics of theophylline,57 ? 1>74,76 a n d therefore have the 
potential to alter the effect of rifampin administration on theophyl-
line kinetics. Although the doses of aminophylline used in this study 
were similar to the loading doses used in treating patients, these 
doses were administered as two single doses separated by two weeks. 
Chronic dosing of theophylline could potentially yield different 
results. Although differences in population and dosing are apparent, 
the effect of rifampin on theophylline clearance and elimination in 
patients should be expected to be similar to the effect seen in the 
subjects of this study. Therefore, all patients stabilized on theophyl-
line who are then started on rifampin should be monitored for signs of 
* 
decreased effect of theophylline; and those patients stabilized on both 
drugs who then stop taking the rifampin should be evaluated for signs 
of theophylline toxicity. 
CONCLUSION 
This study demonstrated that rifampin increased the clearance rate 
and the terminal elimination rate constant, and decreased the area 
under the serum theophylline concentration versus time curve and the 
terminal elimination half-life of theophylline in ten healthy, nonsmok-
ing males who were 23 to 42 years old. Rifampin did not cause a 
consistent change in the apparent volume of distribution (of the 
terminal phase) of theophylline in those subjects. The results of this 
study should alert clinicians to monitor patients for signs of either 
theophylline toxicity when rifampin therapy is discontinued from a 
background regimen of theophylline therapy, or of diminished theophyl-
line effect when rifampin is added in a patient stabilized on theophyl-
line . 
FIGURES 
For Figures 2 through 13: 
Theophylline Serum Concentrations missing 
or less than the lower limit of detection 
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Figure 2, Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #1 before ( O ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.0 







































figure 3, Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject //2 before ( 0 ) and at the end of ( • ) 
two weeks of rifampin administration- These data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.7 
and 6.8 mg/kg respectively. 
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Figure 4, Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #3 before ( O ) and at the end of ( • ) 
two weeks of rifampin administration. These- data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.2 
and 6.0 mg/kg respectively. 
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Figure 5. Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #4 before ( O ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-





































Figure 6. Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #5 before ( O ) and at the end of ( • ) 
two weeks of rifampin administration. , These data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.0 
mg/kg. 
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Figure 7, Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #6 before ( O ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.1 
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Figure 8. Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #7 before ( 0 ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-
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Figure 9. Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #8 before ( Q ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.0 
and 6.1 mg/kg respectively. 
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Figure 10. Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject //9 before ( o ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-
lowing single intravenous infusions of aminophylline at doses of 6.0 
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Figure 11. Semi-logarithmic plot of theophylline serum concentration 
versus time data from Subject #10 before ( O ) and at the end of ( • ) 
two weeks of rifampin administration. These data were obtained fol-
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Figure 12. Semi-logarithmic plot of the mean (dots) plus or minus one 
standard deviation (lines) of the theophylline serum concentrations at 
each scheduled time of blood sampling. Each mean point represents 
data collected from all ten subjects unless indicated by the number of 
subjects in brackets next to that point. These data were obtained 
following single intravenous infusions of aminophylline before ( o ) 
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Figure 13. Semi-logarithmic plot of the mean (dots) plus or minus one 
standard deviation (lines) of the theophylline,serum concentrations at 
each scheduled time of blood sampling. Each mean point represents 
data collected from eight subjects (Subjects #2 and #5 were excluded) 
unless indicated by the number of subjects in brackets next to that 
point. These data were obtained following single intravenous infu-
sions of aminophylline before ( 0 ) and at the end of ( • ) two weeks 
of rifampin administration. 
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TABLE 1: AREA UNDER THE THEOPHYLLINE SERUM CONCENTRATION VERSUS TIME 
CURVE (AUC) BEFORE AND AT THE END OF RIFAMPIN ADMINISTRATION IN 
HEALTHY VOLUNTEERS (PERCENT EXTRAPOLATED IS ALSO INCLUDED). 
BEFORE RIFAMPIN 
SUBJECT AUC PERCENT 
NUMBER (mg-hr/L) EXTRAPOLATED 
1 70 18 
2 170 19 
3 120 13 
4 94 5 
5 119 10 
6 75 6 
7 107 13 
8 80 24 
9 93 25 






AUC PERCENT DECREASE 
(mg-hr/L) EXTRAPOLATED IN AUC 
54 8 23 
105 6 38 
86 6 28 
64 12 32 
92 4 23 
59 14 21 
85 5 20 
60 13 25 
55 13 41 
98 22 10 
76 27 
19 
TABLE 2: CLEARANCE RATE OF THEOPHYLLINE BEFORE AND AT THE END OF 
RIFAMPIN ADMINISTRATION IN HEALTHY VOLUNTEERS. 
CLEARANCE (ml/mln/kg) 
SUBJECT BEFORE AFTER PERCENT 
NUMBER RIFAMPIN RIFAMPIN INCREASE 
1 1i22 1•54 26 
2 0.56 0.92 64 
3 0.73 0.98 34 
4 0.90 1.33 48 
5 0.71 0.93 31 
6 1.16 1.50 29 
7 0.80 1.01 26 
8 1.06 1.45 37 
9 0.92 1.52 65 
10 0.78 0.87 12 
MEM 0.88 1.21 40 
STANDARD 
DEVIATION 0.21 0.29 
37 
TABLE 3: TERMINAL ELIMINATION RATE CONSTANT (BETA) OF THEOPHYLLINE 
















































MEAN 0.104 0.149 44 
STANDARD 
DEVIATION 0.023 0.029 
38 
TABLE 4: TERMINAL ELIMINATION HALF-LIFE (T 1/2) OF THEOPHYLLINE BEFORE 
AND AT THE END OF RIFAMPIN ADMINISTRATION IN HEALTHY VOLUNTEERS 























































TABLE 5: TERMINAL PHASE VOLUME OF DISTRIBUTION (Vd) OF THEOPHYLLINE 
BEFORE AND AT THE END OF RIFAMPIN ADMINISTRATION IN HEALTHY VOLUNTEERS. 
Vd (L/kg) 
SUBJECT BEFORE AFTER PERCENT 
NUMBER RIFAMPIN RIFAMPIN CHANGE 
1 0.50 0.45 -10 
2 0.49 0.47 - 4 
3 0.54 0.52 - 4 
4 0.44 0.49 +11 
5 0.44 0.45 + 2 
6 0.57 0.59 + 4 
7 0,57 0.49 -14 
8 0.54 0.52 - 4 
9 0.47 0.56' +19 
10 0.52 0.42 -19 
MEAN 0.51 0.50 - 1 
STANDARD 





This appendix contains the equations used in this study. 
Definitions of Symbols: 
Anti-Ln - Natural antilogarithm. 
Cp± - The serum theophylline concentration of the 'i'th 
sample. 
Ln - Natural logarithm. 
M - The sample number of the peak serum theophylline 
concentration following the aminophylline infusion. 
N - The sample number of the last measurable serum 
theophylline concentration following the 
aminophylline infusion. 
- The time value of the 'i'th sample. 
Z - The number of samples used to determine the 
terminal phase of elimination. 
Ideal Weight Determination: 
Ideal Weight = 50 kg + [(Height [inches] - 60) X 2.3 kg/inch] 
(kg) 
Area Under the Serum Concentration Versus Time Curve: 
Linear Trapezoidal Analysis (AUC-LIN): 
<c'i-i+ C V x ( Ti - ^ -i) AUC-LIN - E 
i=2 
Logarithmic Trapezoidal Analysis (AUC-LOG): 
N (Cp - C P j) X ( T j - T ^ ) 
AUC-LOG 
j-M+1 (Ln [CPj_1 / CPj]) 
Extrapolation Analysis (AUC-EXTRAP): 
AUC-EXTRAP = CpN / Beta (Beta is defined below) 
Total Area Under the Curve (AUC-TOT): 
AUC-TOT - AUC-LIN + AUC-LOG + AUC-EXTRAP 
APPENDIX 1 (continued) 
Clearance Rate: 
Clearance = (Dose of Aminophylline) X 0.85 
(AUC-TOT) X Subject's Weight 
Terminal Elimination Rate Constant (Beta): 
(E [In Cp]) X ( I [T]) - I (T X Ln Cp) 
Beta = • 2 
£ (T2) - ( I [T])2 
Terminal Elimination Half-Life (T%); 
Th - 0.693 / Beta 
Apparent Volume of Distribution of the Terminal Phase (Vd) : 
0.85 X (Dose of Aminophylline) 
Vd = Subject's ( l[Ln Cp] + Z[T] - Beta) 
Weight X Anti-Ln Z 
Correlation Coefficient (R) : 
Beta 
Beta = 
I ([Ln Cp]2) - (E [Ln Cp])' 
Z 
Coefficient of Determination: 
2 
Coefficient of Determination = R 
t-Statistic of the Correlation Coeffient: 
t ( 2_ 2 ) - R /z-2 
/ T T 7 
APPENDIX 2 
INFORMED CONSENT FORM 
You are invited to participate in the research project entitled; 
"THE EFFECT OF RIFAMPIN ON THEOPHYLLINE PHARMACOKINETIC PARAMETERS 
(FOLLOWING INTRAVENOUS AMINOPHYLLINE) IN NORMAL VOLUNTEERS". 
The purpose of this study is to determine whether or not the drug 
rifampin can cause an increase or decrease in the blood level or rate 
of disappearance from the blood of another drug, theophylline. 
Rifampin is an antibiotic used to treat tuberculosis and other 
bacterial infections, and has increased the disappearance of many drugs 
from the blood. Theophylline is useful in treating patients with 
certain lung diseases such as asthma. The disappearance of 
theophylline from blood has been increased or decreased by a variety of 
drugs. Aminophylline is the injectable form of theophylline. Both 
rifampin and theophylline (aminophylline) have been approved for use in 
humans for many years, but the interaction between these two drugs has 
never been studied and reported in humans. The information from this 
study will be useful in anticipating theophylline dosage adjustments in 
patients in whom rifampin is to be started. 
Ten healthy nonsmoking male volunteers, 18 to 45 years old, will 
be participants in this project. Before the study begins you will 
undergo a screening visit which will include a physical examination, 
medical and medication history, blood tests, and urinalysis. The blood 
tests will involve obtaining 25 milliliters (ml) or two tablespoonfuls 
by venipuncture. The following tests will be run on the samples: liver 
and kidney function tests, electrolytes, red and white blood cell 
count, and other blood chemistries. 
If found eligible to participate in this project, you will be 
scheduled to come to the hospital one morning to receive aminophylline 
injected in a vein in one arm. One teaspoonful (5 ml) of blood will be 
obtained at the beginning of the aminophylline infusion and then at 
various scheduled times over the next 24 hours for a total of 11 
samples. You will need to be in the hospital for the first 8 hours, 
and you will need to return for the 12 and 24 hour blood samples. You 
will also be asked to collect all your urine over those 24 hours 
following the aminophylline administration. You will then be started 
on rifampin 600 mg per day to be taken by mouth in one dose each 
morning between 7:00 and 9:00 AM for 14 days. On the 14th day of 
rifampin, you will again be scheduled to come into the hospital and 
repeat the administration of aminophylline as outlined above (including 
blood sampling and urine collection). The blood and urine tests done 
during the screening visit will be  repeated. The amount of blood 
obtained for this entire study will be approximately 6 ounces (less 
than one cup). 
There are certain risks associated with this project. Commonly 
occurring side effects from rifampin include diarrhea, stomach cramps, 
and a reddish orange to reddish brown discoloration of urine, stools, 
saliva, sweat and tears. Commonly occurring side effects from 
theophylline or aminophylline include nausea, vomiting, stomach pain, 
nervousness, irritability, restlessness, headache, and rapid and/or 
pounding heatbeat. Some pain or bruising may occur at the site of 
blood drawing. There may be other risks that are unforeseen or that 
occur less commonly. Serious problems are not anticipated, but if they 
occur you will be withdrawn from the study, treated appropriately and 
followed until they resolve. 
Certain procedures must be followed as closely as possible to 
decrease the chance of drug toxicity and to help with the proper 
conduction of this study. You will be asked not to take any medication 
(or drug) while you are participating in this project. If you need to 
take a drug, please check-with the investigator beforehand if at all 
possible. You should not consume any alcoholic beverages while on 
rifampin or for two days before or after. Nothing should be smoked 
while participating in this study. This includes cigarettes, cigars, 
pipes, and marijuana. Caffeine intake should be restricted two days 
before and one day after aminophylline administration. Caffeine is 
found in many beverages (soft drinks, coffee, tea, cocoa, chocolate) 
and drugs (No Doz, Anacin, Excedrin, Dexatrim, Doan's Pills, Dewitt's 
Pills, Synalgos, Darvon Compound, Cafergot, and many others). If any 
of the above drugs or substances are used by you, please inform the 
investigator soon afterward. 
The benefits to you will include a free physical examination, free 
anlaysis of blood and urine, and $75.00 remuneration for completion of 
the study. If you need to be withdrawn from the study at the 
discretion of the investigator for an adverse effect, remuneration will 
be pain in full. Other reasons for withdrawal from the study will 
usually not result in any payment. You many be withdrawn from this 
study at any time at your own discretion. If you stop participation in 
this project you will not jepardize your future medical care or 
participation in other projects. 
If you have any questions now or later, please ask them. The 
following telephone numbers are provided to you if questions or 
problems arise in the future: Eric Boyce (day) 581-5941 or (evening 
and night) 484-6317; George Dukes, Pharm.D. (day) 581-6257. 
Medical treatment or compensation for physical Injury: In the 
event you sustain physical injury resulting from the research project 
in which you are participating, the University of Utah will provide 
you, without charge, emergency and temporary medical treatment not 
otherwise covered by insurance. Furthermore, if your injuries are 
caused by negligent acts or omissions of University employees acting in 
the course and scope of their employment, the Universtiy may be liable, 
subject to limitations prescribed by law, for additional medical costs 
and other damages you sustain. If you believe that you have suffered a 
physical injury as a result of participation in this research program, 
please contact the Office of Research Administration, telephone number 
581-6903. 
Every reasonable effort will be made to keep your medical records 
confidential, and they will not be released without your consent. 
These records may be inspected by the Food and Drug Administration. 
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Any publication of the information obtained in this project will not 
identify you by name or picture. 
I have read this Informed Consent Form for the research poject 
entitled "The Effect of Rifampin on Theophylline Pharmacokinetic 
Parameters (Following Intravenous Aminophylline) in Normal Volunteers". 
This study has also been explained to me verbally. I have had the 
opporunity to ask questions and my questions have been answered 
adequately. I also understand that I may ask questions at any time 
during the course of this project. 
I voluntarily agree to participate in this research project. 
Participant's Signature Date 
Witness' Signature Investigator's Signature 
• 
SCREENING VISIT 
Subject's Initials Study Number Date 
(If eligible) 
Physical Examination: Age years male 
B.P. / HR RR Temp °C or °F 
Weight lbs. or kg Height in. or cm. 
Calculated IBW Wt/IBW 
Any Abnormalities Noted on Physical Examination? 
If Yes, please describe briefly; 
Medical History: 





No; if Yes, describe: 
Medication History: 
List any chronic medications, Any medications taken ln last 2 
weeks, or any influenza vaccine in the last month: 
Dates: 
Medication Dose Started & Stopped Reason 
Allergies: 
Does the Subject report any allergies? 
Specifically, to: Aminophylline; Theophylline; 
Rifampin; Caffeine; Heparin; Other (specify) 
Describe Reactions (nature, dose, route of administration, dates, 
severity, subsequent reactions, sequelae, etc.): 
Laboratory Test Abnormalities: 
Test Value Normal Range % Change from Normal 
AMINOPHYLLINE ADMINISTRATION VISITS 
Subject's Initials Study Number Date 
Visit; Pre-Rifampin Post-Rifatnpin 
Aminophylline Administration: 
























H • R» 
Weight Kg or lbs (= kg) 
Any Caffeine-Containing beverages or medications in last 2 days? 
If yes, describe: 
Any Alcoholic beverages since the last visit? 
If yes, describe: 
Any Smoking or Medication taken since the last visit? 
If yes, describe: 
RIFAMPIN ADMINISTRATION LOG 
Subject's Initials Study Number 
Date Rifampin Started 
Last Date of Rifampin Therapy 
OTHER MEDICATIONS, DOSES MISSED, 















Prescribed dosage: tablets per day in one dose in the morning. 
Number of tablets given Strength of tablets mg 
Number of tablets returned Reasons for missed doses: 
Number of missed do 
Side Effects: 
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